| Literature DB >> 16274414 |
Arthur J Moss1, Mary W Brown, David S Cannom, James P Daubert, Mark Estes, Elyse Foster, Henry M Greenberg, W Jackson Hall, Steven L Higgins, Helmut Klein, Mark Pfeffer, David Wilber, Wojciech Zareba.
Abstract
The planned MADIT-CRT trial is designed to determine if CRT-D will reduce the risk of mortality and HF events by approximately 25% in subjects with ischemic (NYHA class I-II) and non-ischemic (NYHA class II) cardiomyopathy, left ventricular dysfunction (EF<or=0.30), and prolonged intraventricular conduction (QRS duration>or=130 ms).Entities:
Mesh:
Year: 2005 PMID: 16274414 PMCID: PMC6932697 DOI: 10.1111/j.1542-474X.2005.00073.x
Source DB: PubMed Journal: Ann Noninvasive Electrocardiol ISSN: 1082-720X Impact factor: 1.468